USD 0.4497
↑ 0.0017 (0.38%)
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| UNCY | 0.4 | -22.5 | 12.4 | 49.9 | -58.4 | -13.9 | -83.1 | -91.0 | -91.0 | -91.0 |
| S&P 500 | -1.3 | -1.8 | 0.9 | 5.9 | 10.6 | 30.3 | 25.3 | 88.1 | 187.5 | 33134.0 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | UNCY |
| name | Unicycive Therapeutics, Inc. |
| price | 0.4497 |
| changes percentage | 0.3804 |
| change | 0.0017 |
| day low | 0.4191 |
| day high | 0.4584 |
| year high | 1.818 |
| year low | 0.202 |
| market cap | 42431983 |
| price avg 50 | 0.42922 |
| price avg 200 | 0.78617 |
| exchange | NASDAQ |
| volume | 1136291 |
| avg volume | 1801165 |
| open | 0.4499 |
| previous close | 0.448 |
| eps | -0.34 |
| pe | -1.32 |
| earnings announcement | 2024-11-12T05:00:00.000+0000 |
| shares outstanding | 94356200 |
| timestamp | 2024-11-15 17:23:51 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001766140 | |||
| revenue | 675000 | 951000 | -29.02 |
| gross profit | 391000 | 944000 | -58.58 |
| gross profit ratio | 0.58 | 0.99 | -41.64 |
| research and development expenses | 12902000 | 12436000 | 3.75 |
| operating expenses | 21449000 | 19003000 | 12.87 |
| interest income | 615000 | 6000 | 10150.00 |
| interest expense | 82000 | 6000 | 1266.67 |
| ebitda | -30178000 | -18045000 | -67.24 |
| ebitdaratio | -44.71 | -18.98 | -135.53 |
| operating income | -20774000 | -18052000 | -15.08 |
| operating income ratio | -30.78 | -18.98 | -62.13 |
| net income | -30544000 | -18064000 | -69.09 |
| net income ratio | -45.25 | -18.99 | -138.23 |
| eps | -1.28 | -1.2 | -6.67 |
Revenue Growth: revenue decreased to 1 million in 2023 from 1 million in 2022 representing a change of -29.02%. This indicates a sales shrinking, which is a negative sign for the company.
Gross Profit: Gross Profit decreased to 0 million in 2023 from 1 million in 2022 representing a change of -58.58%. This indicates a sales profitability decline, which is a negative sign for the company.
Operating Expenses: Operating Expenses increased to 21 million in 2023 from 19 million in 2022 representing a change of 12.87%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
Earnings per Share (EPS): EPS increased to -1.28 in 2023 from -1.28 in 2022 representing a change of -6.67%. This indicates that the company's earnings are decreasing and it is becoming less profitable on a per-share basis.
Research and Development (R&D) Expenses: R&D Expenses increased to 13 million in 2023 from 12 million in 2022 representing a change of 3.75%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to -30 million in 2023 from -18 million in 2022 representing a change of -67.24%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to -21 million in 2023 from -18 million in 2022 representing a change of -15.08%. The increase in operating income indicates better operational performance and increased profitability.
Net Income: Net income increased to -31 million in 2023 from -18 million in 2022 representing a change of -69.09%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001766140 | |||
| revenue | 0 | 0 | NaN |
| gross profit | 0 | 0 | NaN |
| gross profit ratio | 0 | 0 | NaN |
| research and development expenses | 3045000 | 4868000 | -37.45 |
| operating expenses | 6251000 | 7401000 | -15.54 |
| interest income | 416000 | 462000 | -9.96 |
| interest expense | -15000 | 16000 | -193.75 |
| ebitda | -6251000 | -7401000 | 15.54 |
| ebitdaratio | 0 | 0 | NaN |
| operating income | -6251000 | -7401000 | 15.54 |
| operating income ratio | 0 | 0 | NaN |
| net income | -4096000 | 3930000 | -204.22 |
| net income ratio | 0 | 0 | NaN |
| eps | -0.05 | -0.36 | 87.19 |
Research and Development (R&D) Expenses: R&D Expenses decreased to 3 million in 2024Q3 from 5 million in 2024Q2 representing a change of -37.45%. This shows that the company decreased investment in innovation and product development, which is not a good sign for long-term growth.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to -6 million in 2024Q3 from -7 million in 2024Q2 representing a change of 15.54%. The decrease in EBITDA indicates declined operational efficiency and profitability.
Operating Income: Operating income decreased to -6 million in 2024Q3 from -7 million in 2024Q2 representing a change of 15.54%. The decrease in operating income indicates worse operational performance and decreased profitability.
Net Income: Net income decreased to -4 million in 2024Q3 from 4 million in 2024Q2 representing a change of -204.22%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
Operating Expenses: Operating Expenses decreased to 6 million in 2024Q3 from 7 million in 2024Q2 representing a change of -15.54%. The decrease in operating expenses can be attributed to various factors such as improved profitability, cost optimization and financial stability, lower operating expenses can be positive indicators.
Earnings per Share (EPS): EPS increased to -0.05 in 2024Q3 from -0.05 in 2024Q2 representing a change of 87.19%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001766140 | |||
| total assets | 14191000 | 2818000 | 403.58 |
| total liabilities | 18000000 | 3284000 | 448.11 |
| total equity | -3809000 | -466000 | -717.38 |
| cash and cash equivalents | 9701000 | 455000 | 2032.09 |
| short term investments | 0 | 0 | NaN |
| long term investments | 0 | 0 | NaN |
| total current assets | 13399000 | 2644000 | 406.77 |
| total non current assets | 792000 | 174000 | 355.17 |
| total current liabilities | 17534000 | 3284000 | 433.92 |
| total non current liabilities | 466000 | 1047 | 44408.12 |
| common stock | 35000 | 15000 | 133.33 |
| retained earnings | -64541000 | -33997000 | -89.84 |
| total debt | 811000 | 155000 | 423.23 |
Total Assets: Total Assets increased to 14 million in 2023 from 3 million in 2022 representing a change of 403.58%. Suggesting a growth in asset holdings.
Cash And Cash Equivalents: Cash And Cash Equivalents increased to 10 million in 2023 from 0 million in 2022 representing a change of 2032.09%. This indicates an increase in available liquid assets.
Total Current Assets: Total Current Assets increased to 13 million in 2023 from 3 million in 2022 representing a change of 406.77%. This indicates a better liquidity position.
Common Stock: Common Stock increased to 0 in 2023 from 0 in 2022 representing a change of 133.33%. This indicates an increase in ownership interest.
Total Liabilities: Total Liabilities increased to 18 million in 2023 from 3 million in 2022 representing a change of 448.11%. This indicates an increase in overall liabilities.
Total Equity: Total Equity decreased to -4 million in 2023 from 0 million in 2022 representing a change of -717.38%. This indicates a decrease in shareholders' equity.
Total Current Liabilities: Total Current Liabilities increased to 18 million in 2023 from 3 million in 2022 representing a change of 433.92%. This indicates a higher short-term debt burden.
Retained Earnings: Retained Earnings decreased to -65 million in 2023 from -34 million in 2022 representing a change of -89.84%. This indicates an accumulated losses.
Total Debt: Total Debt increased to 1 million in 2023 from 0 million in 2022 representing a change of 423.23%. This indicates an increase in overall debt burden.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001766140 | |||
| total assets | 38574000 | 44701000 | -13.71 |
| total liabilities | 10724000 | 13360000 | -19.73 |
| total equity | 27850000 | 31341000 | -11.14 |
| cash and cash equivalents | 32347000 | 41780000 | -22.58 |
| short term investments | 0 | 0 | NaN |
| long term investments | 0 | 0 | NaN |
| total current assets | 37741000 | 44054000 | -14.33 |
| total non current assets | 833000 | 647000 | 28.75 |
| total current liabilities | 10459000 | 13086000 | -20.07 |
| total non current liabilities | 265000 | 274000 | -3.28 |
| common stock | 98000 | 43000 | 127.91 |
| retained earnings | -79745000 | -75649000 | -5.41 |
| total debt | 807000 | 634000 | 27.29 |
Total Assets: Total Assets decreased to 39 million in 2024Q3 from 45 million in 2024Q2 representing a change of -13.71%. Suggesting a decrease in asset holdings.
Total Equity: Total Equity decreased to 28 million in 2024Q3 from 31 million in 2024Q2 representing a change of -11.14%. This indicates a decrease in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 32 million in 2024Q3 from 42 million in 2024Q2 representing a change of -22.58%. This indicates a decrease in available liquid assets.
Total Current Assets: Total Current Assets decreased to 38 million in 2024Q3 from 44 million in 2024Q2 representing a change of -14.33%. This indicates a worsen liquidity position.
Retained Earnings: Retained Earnings decreased to -80 million in 2024Q3 from -76 million in 2024Q2 representing a change of -5.41%. This indicates an accumulated losses.
Total Debt: Total Debt increased to 1 million in 2024Q3 from 1 million in 2024Q2 representing a change of 27.29%. This indicates an increase in overall debt burden.
Total Liabilities: Total Liabilities decreased to 11 million in 2024Q3 from 13 million in 2024Q2 representing a change of -19.73%. This indicates a decrease in overall liabilities.
Total Current Liabilities: Total Current Liabilities decreased to 10 million in 2024Q3 from 13 million in 2024Q2 representing a change of -20.07%. This indicates a lower short-term debt burden.
Common Stock: Common Stock increased to 0 in 2024Q3 from 0 in 2024Q2 representing a change of 127.91%. This indicates an increase in ownership interest.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001766140 | |||
| net change in cash | 9246000 | -16124000 | 157.34 |
| operating cash flow | -18283000 | -15651000 | -16.82 |
| free cash flow | -18295000 | -15653000 | -16.88 |
| capital expenditure | -12000 | -2000 | -500.00 |
| depreciation and amortization | 284000 | 161000 | 76.40 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 1767000 | 1047000 | 68.77 |
| accounts payables | 1276000 | 1267000 | 0.71 |
| inventory | 0 | 0 | NaN |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | -12000 | -2000 | -500.00 |
| net cash used for investing activites | -12000 | -2000 | -500.00 |
| debt repayment | 0 | 0 | NaN |
| common stock issued | 28037000 | 11000 | 254781.82 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 27541000 | -471000 | 5947.35 |
| cash at end of period | 9701000 | 455000 | 2032.09 |
| accounts receivables | 0 | 0 | NaN |
| cash at beginning of period | 455000 | 16579000 | -97.26 |
Net Change in Cash: Net Change in Cash increased to 9 million in 2023 from -16 million in 2022 representing a change of 157.34%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Capital Expenditure: Capital Expenditure decreased to 0 million in 2023 from 0 million in 2022 representing a change of -500.0%. This indicates a possible improved efficiency or a shift in the company's strategic priorities.
Operating Cash Flow: Operating Cash Flow decreased to -18 million in 2023 from -16 million in 2022 representing a change of -16.82%. This indicates that the company generated less cash from its core business operations.
Free Cash Flow: Free Cash Flow decreased to -18 million in 2023 from -16 million in 2022 representing a change of -16.88%. This indicates a decrease in cash generated after accounting for capital expenditures.
Stock-Based Compensation: Stock-Based Compensation increased to 2 million in 2023 from 1 million in 2022 representing a change of 68.77%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables increased to 1 million in 2023 from 1 million in 2022 representing a change of 0.71%. This indicates that the company has increased its outstanding obligations to its suppliers.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001766140 | |||
| operating cash flow | -9252000 | -6319000 | -46.42 |
| free cash flow | -9276000 | -6339000 | -46.33 |
| capital expenditure | -24000 | -20000 | -20.00 |
| depreciation and amortization | 123000 | -113000 | 208.85 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 605000 | 641000 | -5.62 |
| accounts receivables | 0 | 0 | NaN |
| accounts payables | -631000 | 0 | NaN |
| inventory | 0 | 0 | NaN |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | -24000 | -20000 | -20.00 |
| net cash used for investing activites | -24000 | -20000 | -20.00 |
| debt repayment | 0 | 0 | NaN |
| common stock issued | -50000000 | 0 | NaN |
| common stock repurchased | -13088427000 | 13088427000 | -200.00 |
| dividends paid | -208000 | -1095000 | 81.00 |
| net cash used provided by financing activities | -157000 | -811000 | 80.64 |
| net change in cash | -9433000 | -7150000 | -31.93 |
| cash at end of period | 32347000 | 41780000 | -22.58 |
| cash at beginning of period | 41780000 | 48930000 | -14.61 |
Net Change in Cash: Net Change in Cash decreased to -9 million in 2024Q3 from -7 million in 2024Q2 representing a change of -31.93%. Indicating a declined ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow decreased to -9 million in 2024Q3 from -6 million in 2024Q2 representing a change of -46.42%. This indicates that the company generated less cash from its core business operations.
Free Cash Flow: Free Cash Flow decreased to -9 million in 2024Q3 from -6 million in 2024Q2 representing a change of -46.33%. This indicates a decrease in cash generated after accounting for capital expenditures.
Accounts Payables: The absolute value of Accounts Payables increased to 1 million in 2024Q3 from 0 million in 2024Q2 representing a change of nan%. This indicates that the company has increased its outstanding obligations to its suppliers.
Capital Expenditure: Capital Expenditure decreased to 0 million in 2024Q3 from 0 million in 2024Q2 representing a change of -20.0%. This indicates a possible improved efficiency or a shift in the company's strategic priorities.
Stock-Based Compensation: Stock-Based Compensation decreased to 1 million in 2024Q3 from 1 million in 2024Q2 representing a change of -5.62%. This indicates decreased expenses, which is generally considered a positive sign from a financial perspective.
Dividends Paid: Dividends Paid increased to 0 million in 2024Q3 from -1 million in 2024Q2 representing a change of 81.0%. This indicates a stronger financial position, more confidence in future prospects, and a better commitment to returning value to shareholders.
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2023-12-31 | 2022-12-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 0.03 | 0.06 | -56.45 |
| net income per share | -1.24 | -1.2 | -3.75 |
| operating cash flow per share | -0.75 | -1.04 | 28.32 |
| free cash flow per share | -0.75 | -1.04 | 28.28 |
| cash per share | 0.4 | 0.03 | 1208.23 |
| book value per share | -0.16 | -0.03 | -401.54 |
| tangible book value per share | -0.16 | -0.03 | -401.54 |
| shareholders equity per share | -0.16 | -0.03 | -401.54 |
| interest debt per share | 0.0 | 0.01 | -61.89 |
| market cap | 21292758.42 | 8130806.46 | 161.88 |
| enterprise value | 12402758.42 | 7830806.46 | 58.38 |
| pe ratio | -0.7 | -0.45 | -54.88 |
| price to sales ratio | 31.54 | 8.55 | 268.96 |
| pocfratio | -1.16 | -0.52 | -124.18 |
| pfcf ratio | -1.16 | -0.52 | -124.06 |
| pb ratio | -5.59 | -17.45 | 67.96 |
| ptb ratio | -5.59 | -17.45 | 67.96 |
| ev to sales | 18.37 | 8.23 | 123.15 |
| enterprise value over ebitda | -0.41 | -0.43 | 5.29 |
| ev to operating cash flow | -0.68 | -0.5 | -35.58 |
| ev to free cash flow | -0.68 | -0.5 | -35.51 |
| earnings yield | -1.43 | -2.22 | 35.43 |
| free cash flow yield | -0.86 | -1.93 | 55.37 |
| debt to equity | -0.0 | -0.33 | 98.58 |
| debt to assets | 0.0 | 0.06 | -97.69 |
| net debt to ebitda | 0.29 | 0.02 | 1671.93 |
| current ratio | 0.76 | 0.81 | -5.09 |
| interest coverage | -253.34 | -3008.67 | 91.58 |
| income quality | 0.6 | 0.87 | -30.94 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 12.66 | 6.91 | 83.37 |
| research and ddevelopement to revenue | 19.11 | 13.08 | 46.17 |
| intangibles to total assets | 0 | 0 | NaN |
| capex to operating cash flow | -0.0 | -0.0 | -413.62 |
| capex to revenue | 0.02 | 0.0 | 745.33 |
| capex to depreciation | 0.04 | 0.01 | 240.14 |
| stock based compensation to revenue | 2.62 | 1.1 | 137.78 |
| graham number | 2.08 | 0.91 | 128.11 |
| roic | 5.48 | 58.06 | -90.56 |
| return on tangible assets | -2.15 | -6.41 | 66.42 |
| graham net net | -0.34 | -0.19 | -80.00 |
| working capital | -4135000 | -640000 | -546.09 |
| tangible asset value | -3809000 | -466000 | -717.38 |
| net current asset value | -4601000 | -640000 | -618.91 |
| invested capital | -3343000 | -466000 | -617.38 |
| average receivables | 0 | 0 | NaN |
| average payables | 833500 | 779500 | 6.93 |
| average inventory | 0 | 0 | NaN |
| days sales outstanding | 0 | 0 | NaN |
| days payables outstanding | 1055.16 | 44112.86 | -97.61 |
| days of inventory on hand | 0 | 0 | NaN |
| receivables turnover | 0 | 0 | NaN |
| payables turnover | 0.35 | 0.01 | 4080.69 |
| inventory turnover | 0 | 0 | NaN |
| roe | 8.02 | 38.76 | -79.31 |
| capex per share | 0.0 | 0.0 | 268.15 |
ROE: Return on Equity (ROE) decreased to 8.02 on 2023-12-31 from 38.76 on 2022-12-31, representing a change of -79.31%. However, ROE is >= 15%, suggesting that the company has been generating high returns for its shareholders still.
Debt-to-Equity Ratio: Debt-to-Equity Ratio increased to -0.00 on 2023-12-31 from -0.33 on 2022-12-31, representing a change of 98.58%. The debt-to-equity ratio has been increasing, indicating that the company has been relying more on debt financing. Higher leverage may increase financial risk. However, a ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to -0.70 on 2023-12-31 from -0.45 on 2022-12-31, representing a change of -54.88%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio decreased to 0.76 on 2023-12-31 from 0.81 on 2022-12-31, representing a change of -5.09%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Also, it's below 1, indicating potential liquidity issues.
| 2024-09-30 Q3 | 2024-06-30 Q2 | Q/Q change % | |
|---|---|---|---|
| UNCY | |||
| calendar year | 2024 | 2024 | NaN |
| revenue per share | 0 | 0 | NaN |
| net income per share | -0.05 | 0.1 | -144.43 |
| operating cash flow per share | -0.1 | -0.17 | 37.59 |
| free cash flow per share | -0.1 | -0.17 | 37.62 |
| cash per share | 0.36 | 1.1 | -67.00 |
| book value per share | 0.31 | 0.83 | -62.12 |
| tangible book value per share | 0.31 | 0.83 | -62.12 |
| shareholders equity per share | 0.31 | 0.83 | -62.12 |
| interest debt per share | 0.01 | 0.01 | -10.21 |
| market cap | 36279936.17 | 20473998.48 | 77.20 |
| enterprise value | 4739936.17 | -20672001.52 | 122.93 |
| pe ratio | -2.21 | 1.3 | -270.02 |
| price to sales ratio | 0 | 0 | NaN |
| pocfratio | -3.92 | -3.24 | -21.03 |
| pfcf ratio | -3.91 | -3.23 | -21.09 |
| pb ratio | 1.3 | 0.65 | 99.41 |
| ptb ratio | 1.3 | 0.65 | 99.41 |
| ev to sales | 0 | 0 | NaN |
| enterprise value over ebitda | -0.76 | 2.79 | -127.15 |
| ev to operating cash flow | -0.51 | 3.27 | -115.66 |
| ev to free cash flow | -0.51 | 3.26 | -115.67 |
| earnings yield | -0.11 | 0.19 | -158.82 |
| free cash flow yield | -0.26 | -0.31 | 17.42 |
| debt to equity | 0.03 | 0.01 | 152.27 |
| debt to assets | 0.02 | 0.01 | 159.77 |
| net debt to ebitda | 5.05 | 5.56 | -9.24 |
| current ratio | 3.61 | 3.37 | 7.19 |
| interest coverage | 416.73 | -462.56 | 190.09 |
| income quality | -5.06 | -1.61 | -214.61 |
| dividend yield | 0.01 | 0.05 | -89.28 |
| payout ratio | -0.05 | 0.28 | -118.23 |
| sales general and administrative to revenue | 0 | 0 | NaN |
| research and ddevelopement to revenue | 0 | 0 | NaN |
| intangibles to total assets | 0 | 0 | NaN |
| capex to operating cash flow | -0.0 | -0.0 | 18.04 |
| capex to revenue | 0 | 0 | NaN |
| capex to depreciation | 0.2 | -0.18 | 210.24 |
| stock based compensation to revenue | 0 | 0 | NaN |
| graham number | 0.57 | 1.39 | -58.98 |
| roic | -0.22 | -0.23 | 6.57 |
| return on tangible assets | -0.11 | 0.09 | -220.78 |
| graham net net | 0.24 | 0.75 | -67.57 |
| working capital | 27282000 | 30968000 | -11.90 |
| tangible asset value | 27850000 | 31341000 | -11.14 |
| net current asset value | 27017000 | 30694000 | -11.98 |
| invested capital | 28115000 | 31615000 | -11.07 |
| average receivables | 0 | 0 | NaN |
| average payables | 1010000 | 1356000 | -25.52 |
| average inventory | 0 | 0 | NaN |
| days sales outstanding | 0 | 0 | NaN |
| days payables outstanding | 0 | 0 | NaN |
| days of inventory on hand | 0 | 0 | NaN |
| receivables turnover | 0 | 0 | NaN |
| payables turnover | 0 | 0 | NaN |
| inventory turnover | 0 | 0 | NaN |
| roe | -0.15 | 0.13 | -217.29 |
| capex per share | 0.0 | 0.0 | -48.85 |
ROE: Return on Equity (ROE) decreased to -0.15 on 2024-09-30 Q3 from 0.13 on 2024-06-30 Q2, representing a change of -217.29%. Suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to -2.21 on 2024-09-30 Q3 from 1.30 on 2024-06-30 Q2, representing a change of -270.02%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio increased to 3.61 on 2024-09-30 Q3 from 3.37 on 2024-06-30 Q2, representing a change of 7.19%. The current ratio has been increasing, suggesting an increase in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
Debt-to-Equity Ratio: Debt-to-Equity Ratio increased to 0.03 on 2024-09-30 Q3 from 0.01 on 2024-06-30 Q2, representing a change of 152.27%. The debt-to-equity ratio has been increasing, indicating that the company has been relying more on debt financing. Higher leverage may increase financial risk. However, a ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
Negative Sentiment: Discounted Cash Flow value is 0.39 which is lower than current price 0.45, indicates the company may be overvalued.
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Positive
Publish Date: 2024-11-13 07:15:00
– OLC New Drug Application (NDA) Accepted by the FDA with a PDUFA Target Action Date of June 28, 2025– – Commercial Planning in Progress for 2025 Launch – – Late Breaker Poster Presentation on OLC at ASN Kidney Week – – Successful Completion of UNI-494 Phase 1 Trial – LOS ALTOS, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the three months ended September 30, 2024, and provided a business update.
Sentiment: Positive
Publish Date: 2024-11-11 07:00:00
– FDA sets PDUFA Action Date of June 28, 2025 – Company Preparing for 2025 Commercial Launch – LOS ALTOS, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) and has set a Prescription Drug User Fee Act (PDUFA) target action date of June 28, 2025.
Sentiment: Positive
Publish Date: 2024-10-28 07:03:00
– Late-Breaker Poster Presentation Highlights Favorable Safety & Tolerability of OLC – – Two Publications Recently Issued Featuring OLC and UNI-494 – LOS ALTOS, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that multiple presentations were delivered at the American Society of Nephrology (ASN) Kidney Week 2024 that highlighted the extensive development progress for both oxylanthanum carbonate (OLC) and UNI-494.
Sentiment: Neutral
Publish Date: 2024-10-16 16:35:00
LOS ALTOS, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on Thursday, October 17, 2024 at 10:00 a.m. ET.
Sentiment: Neutral
Publish Date: 2024-10-14 07:03:00
LOS ALTOS, Calif., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that a poster presentation on oxylanthanum carbonate (OLC) was selected for a Late-Breaker session at the American Society of Nephrology (ASN) Kidney Week 2024. Unicycive will also deliver three additional poster presentations on OLC and UNI-494. The conference will take place October 24-27, 2024 in San Diego, CA.
Sentiment: Positive
Publish Date: 2024-10-09 07:03:00
UNI-494 was Well-Tolerated as a Single Dose up to 160 mg and in Multiple Doses at 40 mg Twice-a-Day UNI-494 was Well-Tolerated as a Single Dose up to 160 mg and in Multiple Doses at 40 mg Twice-a-Day
Sentiment: Neutral
Publish Date: 2024-09-24 07:03:00
LOS ALTOS, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer will participate in a fireside chat at the virtual Lytham Partners Fall 2024 Investor Conference on Tuesday, October 1, 2024 at 11:00 a.m. ET.
Sentiment: Neutral
Publish Date: 2024-09-16 07:03:00
LOS ALTOS, Calif., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company" or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer will present a corporate update at the Virtual Life Sciences Investor Forum on Thursday, September 19, 2024 at 2:00 p.m. ET in New York, NY.
Sentiment: Neutral
Publish Date: 2024-09-05 07:03:00
LOS ALTOS, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer will present a corporate update at the H.C. Wainwright 26th Annual Global Investment Conference on Tuesday, September 10, 2024 at 10:30 a.m. ET in New York, NY.
Sentiment: Positive
Publish Date: 2024-09-03 07:03:00
LOS ALTOS, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Oxylanthanum Carbonate (OLC) for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. Unicycive is seeking FDA approval of OLC via the 505(b)(2) regulatory pathway.
Sentiment: Neutral
Publish Date: 2024-08-26 07:03:00
LOS ALTOS, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that three poster presentations will be delivered on the Company's product candidates at the American Society of Nephrology (ASN) Kidney Week 2024 taking place October 24-27, 2024 in San Diego, CA.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
